Pharmacological immunosuppression in solid organ transplant recipients is a significant risk factor in the occurrence of actinic keratosis (AK) and later progression into squamous cell carcinomas (SCC). Treating clinical and preclinical lesions is mandatory in this group of patients due to the high changes of progression into SCC. On the other hand, prevention of AK should be considered because it plays a crucial role.
Several studies have been published on immunocompetent patients, as well as on the management and prevention of AK, but not on immunosuppressed patients.
This review aims to summarize the current knowledge on the management and prevention measures of AK in solid organ transplant recipients.
